Get the Stockscreener App
7.20
1.37%
-0.10
After Hours:
7.27
0.07
+0.97%
Sage Therapeutics Inc Stock (SAGE) Latest News
Sage Therapeutics, Inc. (SAGE): Among the Best Psychedelic Stocks to Buy in 2025 - Yahoo Finance
Levi & Korsinsky Notifies Shareholders of Sage Therapeutics, Inc.(SAGE) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
12 Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
Sage Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your RightsSAGE - ACCESS Newswire
SAGE ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Sage Therapeutics, Inc. Shareholders Who Lost Money - ACCESS Newswire
Sage Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsSAGE - ACCESS Newswire
Sage Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Sage Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024SAGE - ACCESS Newswire
SAGE ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Sage Therapeutics, Inc. investment - ACCESS Newswire
SAGE STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sage Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight - GlobeNewswire Inc.
Is Sage Therapeutics, Inc. (SAGE) the Best Small-Cap Growth Stock to Buy Now? - Insider Monkey
10 Best Small-Cap Growth Stocks to Buy Now - Insider Monkey
Levi & Korsinsky Notifies Sage Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineSAGE - ACCESS Newswire
SAGE STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics - ACCESS Newswire
Sage Therapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before October 28, 2024 to Discuss Your RightsSAGE - ACCESS Newswire
An Investigation Has Commenced on Behalf of Sage Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your SAGE Losses. - ACCESS Newswire
Sage Therapeutics, Inc. (NASDAQ:SAGE) Sees Large Decline in Short Interest - MarketBeat
Sage Therapeutics confirms $7.22 per share acquisition proposal from Biogen - MSN
Analysts Offer Predictions for SAGE Q3 Earnings - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Issues Quarterly Earnings Results - MarketBeat
Wedbush Reiterates "Neutral" Rating for Sage Therapeutics (NASDAQ:SAGE) - MarketBeat
SAGE Therapeutics Faces Legal Challenges: Potential Impact on Financial Stability and Growth - MSN
Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Lags Revenue Estimates - MSN
Q1 Earnings Forecast for SAGE Issued By Leerink Partnrs - MarketBeat
Scotiabank Cuts Sage Therapeutics (NASDAQ:SAGE) Price Target to $12.00 - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Price Target Cut to $8.00 by Analysts at Canaccord Genuity Group - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Receives Neutral Rating from HC Wainwright - MarketBeat
Needham & Company LLC Reaffirms "Hold" Rating for Sage Therapeutics (NASDAQ:SAGE) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out - Markets Insider
Lifshitz Law PLLC Investigates Potential Securities Violations: Sage, SMCI, ZoomInfo & GitLab Under Scrutiny - HPBL
Sage Therapeutics (NASDAQ:SAGE) Earns “Hold” Rating from Needham & Company LLC - Defense World
Sage Therapeutics (NASDAQ:SAGE) Earns “Neutral” Rating from HC Wainwright - Defense World
What is Leerink Partnrs’ Estimate for SAGE Q1 Earnings? - Defense World
SAGE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sage Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the Investigation - Markets Insider
Sage Therapeutics price target lowered to $12 from $14 at Scotiabank - Yahoo Finance
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q4 2024 Earnings Call Transcript - Insider Monkey
Sage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/Y - MSN
Sage Therapeutics (SAGE) to Release Earnings on Tuesday - MarketBeat
(SAGE) Technical Data - Stock Traders Daily
SAGE Therapeutics’ Earnings Call: ZURZUVAE’s Success Amid Challenges - TipRanks
Sage Therapeutics (NASDAQ:SAGE) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Canaccord cuts Sage Therapeutics price target to $8, holds rating - MSN
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Markets Insider
A Glimpse Into The Expert Outlook On Sage Therapeutics Through 7 Analysts - Benzinga
Canaccord cuts Sage Therapeutics price target to $8, holds rating By Investing.com - Investing.com South Africa
Hold Rating on SAGE Therapeutics Amid Underwhelming Sales and Strategic Uncertainties - TipRanks
Sage Therapeutics Inc (SAGE) Q4 2024 Earnings Call Highlights: S - GuruFocus.com
SG Americas Securities LLC Raises Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Cambridge Biopharma Firm Sage Therapeutics Sues Partner Biogen After Buyout Offer - Harvard Crimson
Sage Therapeutics Inc (SAGE) Q4 2024 Earnings Call Highlights: Strong Prescription Growth Amid ... - Yahoo Finance
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):